NVCT
Nuvectis Pharma Inc

822
Loading...
Loading...
News
all
press releases
Nuvectis Pharma CEO Says Increased Dose Intensity Needed To Drive More Efficacy From Ovarian Cancer Lead Drug
Nuvectis Pharma reports mixed Phase 1b results for NXP800 in ovarian cancer, showing antitumor activity and improved safety with adjusted dosing. read more...
Benzinga·10mo ago
News Placeholder
More News
News Placeholder
PESG Releases Market Update: Nuvectis Pharma Shows Promising Synergy for NXP900 in Recent Presentations; Growing Anticipation for Upcoming NXP800 Data Update
Nuvectis Pharma (NASDAQ: NVCT) is gaining momentum following recent presentations at the AACR-NCI-EORTC Symposium, where its SRC/YES1 inhibitor NXP900 demonstrated strong synergy with ALK inhibitors...
Business Wire·11mo ago
News Placeholder
PESG Releases Report on Nuvectis Pharma: With Summit Therapeutics Threatening to Dethrone Merck's Keytruda, Nuvectis' NXP900 is One to Watch
Summit Therapeutics Breakthrough with Ivonescimab The recent breakthrough with Summit Therapeutics Ivonescimab (SMT112) reverberated not just in the medical industry but also across the markets. In...
Business Wire·1y ago
News Placeholder
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
Fort Lee, NJ, March 19, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Globe Newswire·1y ago
News Placeholder
FY2028 Earnings Estimate for Nuvectis Pharma, Inc. Issued By Roth Capital (NASDAQ:NVCT)
Nuvectis Pharma, Inc. (NASDAQ:NVCT Free Report) Stock analysts at Roth Capital upped their FY2028 earnings estimates for Nuvectis Pharma in a research note issued on Thursday...
Zolmax·1y ago
News Placeholder
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovarian Cancer
33% Response Rate and 100% Disease Control Rate Observed in Patients Evaluated for EfficacyComplete Response of Non-Target Tumor Also Observed Platinum-Resistant Ovarian Cancer is a Devastating...
Globe Newswire·1y ago
News Placeholder
Nuvectis Pharma GAAP EPS of -$1.43 beats by $0.16
Nuvectis Pharma GAAP EPS of -$1.43 beats by $0.16...
SeekingAlpha.com: All News·2y ago
News Placeholder
Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights
NXP800 preliminary data update expected this month from the Phase 1b study in platinum resistant, ARID1a mutated ovarian cancer, a program that has been granted Fast Track Designation by the...
Globe Newswire·2y ago
News Placeholder
Correction: Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Globe Newswire·2y ago
News Placeholder
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
Fort Lee, NJ, Feb. 09, 2024 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (NASDAQ: NVCT) ("Nuvectis" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of...
Globe Newswire·2y ago

Latest NVCT News

View

Advertisement. Remove ads.

Advertisement. Remove ads.